Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model
Background: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Journal of Ayurveda and Integrative Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S097594762400130X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846111776043696128 |
|---|---|
| author | Rajesh Shah Gitanjali Talele Nirmal Kumar Kasinathan Madan Barkume Jyoti Kode |
| author_facet | Rajesh Shah Gitanjali Talele Nirmal Kumar Kasinathan Madan Barkume Jyoti Kode |
| author_sort | Rajesh Shah |
| collection | DOAJ |
| description | Background: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses. Objectives: In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models. Method: Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1. Results: The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed. Conclusion: Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode. |
| format | Article |
| id | doaj-art-9121cd8587cf4e90b02a829f7a89ce8c |
| institution | Kabale University |
| issn | 0975-9476 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Ayurveda and Integrative Medicine |
| spelling | doaj-art-9121cd8587cf4e90b02a829f7a89ce8c2024-12-23T04:19:05ZengElsevierJournal of Ayurveda and Integrative Medicine0975-94762024-11-01156101015Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft modelRajesh Shah0Gitanjali Talele1Nirmal Kumar Kasinathan2Madan Barkume3Jyoti Kode4Department of Research, Biosimilia Private Limited, Mumbai, India; Corresponding author. Life Force Foundation Trust, 411-Krushal Commercial Complex, GM Road, Chembur, Mumbai, 400089, India.Department of Research, Biosimilia Private Limited, Mumbai, IndiaAnti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, IndiaAnti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, IndiaAnti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Kode Lab, Tumor Immunology & Immunotherapy (TII) Group, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Homi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai 400094, India; Corresponding author. Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, IndiaBackground: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses. Objectives: In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models. Method: Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1. Results: The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed. Conclusion: Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode.http://www.sciencedirect.com/science/article/pii/S097594762400130XAnticancer activityHomeopathyHIV nosodeHepatitisCancer nosodeXenograft models |
| spellingShingle | Rajesh Shah Gitanjali Talele Nirmal Kumar Kasinathan Madan Barkume Jyoti Kode Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model Journal of Ayurveda and Integrative Medicine Anticancer activity Homeopathy HIV nosode Hepatitis Cancer nosode Xenograft models |
| title | Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model |
| title_full | Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model |
| title_fullStr | Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model |
| title_full_unstemmed | Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model |
| title_short | Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model |
| title_sort | evaluating anticancer potentials of potentized preparations in an in vivo xenograft model |
| topic | Anticancer activity Homeopathy HIV nosode Hepatitis Cancer nosode Xenograft models |
| url | http://www.sciencedirect.com/science/article/pii/S097594762400130X |
| work_keys_str_mv | AT rajeshshah evaluatinganticancerpotentialsofpotentizedpreparationsinaninvivoxenograftmodel AT gitanjalitalele evaluatinganticancerpotentialsofpotentizedpreparationsinaninvivoxenograftmodel AT nirmalkumarkasinathan evaluatinganticancerpotentialsofpotentizedpreparationsinaninvivoxenograftmodel AT madanbarkume evaluatinganticancerpotentialsofpotentizedpreparationsinaninvivoxenograftmodel AT jyotikode evaluatinganticancerpotentialsofpotentizedpreparationsinaninvivoxenograftmodel |